Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.42 |
| ▸ | PRPS1 | P60891 | 1/20 | 0.42 |
| ▸ | HRH2 | P25021 | 1/20 | 0.41 |
| ▸ | CCR3 | P51677 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | FPR2 | P25090 | 1/20 | 0.38 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5453021 | 0.92 | PRPS1 (0.43) | HRH3PRPS1HRH2CCR3BCHE | |
| SCHEMBL5443670 | 0.91 | HRH3 (0.43) | HRH3PRPS1CCR3BCHECNR1 | |
| SCHEMBL5444403 | 0.90 | HRH3 (0.43) | HRH3HRH2CCR3BCHECNR1 | |
| SCHEMBL5460440 | 0.90 | HRH3 (0.42) | HRH3CCR3BCHEEPHX2FPR2 | |
| SCHEMBL14410919 | 0.87 | CCR3 (0.43) | HRH3CCR3BCHEEPHX2 | |
| SCHEMBL14411850 | 0.87 | PRPS1 (0.43) | PRPS1HRH2CCR3BCHECNR1 | |
| SCHEMBL14463811 | 0.86 | PRPS1 (0.42) | HRH3PRPS1HRH2CNR1MAOA | |
| SCHEMBL5481603 | 0.86 | HRH2 (0.46) | PRPS1HRH2CNR1 | |
| SCHEMBL5435101 | 0.84 | HRH3 (0.44) | HRH3CCR3CNR1FPR2PROKR1 | |
| SCHEMBL5451283 | 0.83 | PRPS1 (0.44) | HRH3PRPS1CCR3BCHECNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | GIPR, GHSR, GHRHR | HRH3 527/4885PRPS1 4276/4885HRH2 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.